RNAIII-inhibiting peptide(TFA)
RNAIII-inhibitingpeptide(TFA)是一种有效的Staphylococcusaureus多肽抑制剂，在蜂窝组织炎、角膜炎、化脓性关节炎、骨肌炎和乳腺炎等疾病中有功效。
此产品仅用于科学研究，我们不为任何个人用途提供产品和服务
-
包装价格促销价数量
-
1mg￥2262.001810.00- +
-
5mg￥6737.005390.00- +
- 货号: ajcx13214
- CAS: N/A
- 别名:
- 分子式: C47H57F3N10O13
- 分子量: 1027.01
- 纯度: ＞98%
- 溶解度: DMSO : ≥ 150 mg/mL (146.06 mM)
- 储存: Store at -20°C
- 库存: 现货
Background
RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus, effective in the diseases such as cellulitis, keratitis, septic arthritis, osteomylitis and mastitis.
RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus. RNAIII-inhibiting peptide (RIP) inhibits the synthesis of both RNAII and RNAIII, while RAP activates in wild type S. aureus cells. RNAIII-inhibiting peptide (5 μg/106 cells) potently reduces bacterial cell adhesion to HEp2 cells in the absence of serum, but with slight overall reduction the presence of serum. RNAIII-inhibiting peptide inhibits while RAP induces the phosphorylation of TRAP[1].
RNAIII-inhibiting peptide (20 mg/kg, i.v.) decreases lethality in mice challenged with S. aureus ATCC 25923, with the lethality rate of 70%, and when combined with cefazolin, imipenem, vancomycin, the rates are 20%, 15% and 10%. RNAIII-inhibiting peptide (20 mg/kg, i.v.) also causes decreased lethality in mice challenged with S. aureus Smith, with the lethality rate of 75%, and the lethality rate decreases to 30%, 10% and 10% when combined with cefazolin, imipenem, vancomycin[2].
[1]. Gov Y, et al. RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis. Peptides. 2001 Oct;22(10):1609-20. [2]. Giacometti A, et al. RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis. Peptides. 2005 Feb;26(2):169-75.
Protocol
Animal experiment: | Mice[2]Mice are randomized to receive intravenously isotonic sodium chloride solution (controls C1 and C2) and 20 mg/kg RNAIII-inhibiting peptide alone or combined with 20 mg/kg cefazolin, 10 mg/kg imipenem, or 10 mg/kg vancomycin. Animals are returned to individual cages and monitored for 7 days. The endpoints of the study are quantitative plasma bacterial evaluation and lethality. For each animal model, toxicity is evaluated on the basis of the presence of any drug-related adverse effects, i.e. local signs of inflammation, anorexia, weight loss, vomiting, diarrhea, fever, and behavioral alterations. In particular, to evaluate the physiological effects of RNAIII-inhibiting peptide, temperature, pulse, blood pressure, respirations and oxygenation are monitored in a supplementary RNAIII-inhibiting peptide-treated group without infection[2]. |
参考文献: [1]. Gov Y, et al. RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis. Peptides. 2001 Oct;22(10):1609-20. | |
